二甲双胍及SGLT2抑制剂治疗2型糖尿病合并非酒精性脂肪肝的疗效对比分析  

Comparison of metformin and SGLT2 inhibitors effects on type 2 Diabetes with nonalcoholic fatty liver disease

作　　者：彭茜[1] 李玲[1] PENG Xi;LI Ling(Department Of Endocrinology,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,Sichuan,China)

机构地区：[1]川北医学院附属医院内分泌科,四川南充637000

出　　处：《川北医学院学报》2020年第6期1021-1024,共4页Journal of North Sichuan Medical College

基　　金：四川省教育厅课题(swfz19-y-34)。

摘　　要：目的:探讨二甲双胍及SGLT2抑制剂治疗2型糖尿病合并非酒精性脂肪肝(NAFLD)的效果。方法:选取2型糖尿病合并NAFLD患者62例为研究对象,按治疗方案分为二甲双胍治疗组(n=32)和SGLT2抑制剂治疗组(n=30)。治疗12周后,比较两组各代谢参数的变化情况。结果:治疗12周后,两组患者的体重、HbA1C、FPG、AST、ALT、GGT、TC、TG、LDL-C分别与治疗前比较,差异有统计学意义(P<0.05);SGLT2抑制剂组体重下降较二甲双胍组更为明显(P<0.05);SGLT2抑制剂组可使HDL-C水平明显上升,且与二甲双胍组比较,差异有统计学意义(P<0.05)。结论:二甲双胍及SGLT2抑制剂均可改善2型糖尿病合并NAFLD患者的血糖、血脂、肝脏血清学酶谱,而在改善患者体重、HDL-C水平方面,SGLT2抑制剂显现出更大的优势。Objective:To compare the efficacy of metformin and SGLT2 inhibitors in type 2 Diabetes(T2DM)with nonalcoholic fatty liver disease(NAFLD).Methods:62 patients with T2DM complicated with NAFLD were divided into metformin group(n=32)and SGLT2 inhibitors group(n=30).After 12 weeks of treatment,the changes of metabolic parameters in the two groups were observed.Results:After 12 weeks of treatment,the body weight,HbA1c,FPG,AST,ALT,GGT,TC,TG and LDL-C of the two groups were significantly different from those before treatment(P<0.05).SGLT2 inhibitors group had a greater advantage lowering weight than the metformin group(P<0.05).The level of HDL-C was significantly increased in SGLT2 inhibitor group,and compared with metformin group,the difference was statistically significant(P<0.05).Conclusion:Metformin and SGLT2 inhibitors can improve blood glucose,lipids,and hepatic seronuclease profiles of T2DM patients with NAFLD.In improving the weight and HDL-C levels of these patients,SGLT2 inhibitors showed a greater advantage than metformin.

关 键 词：2型糖尿病 非酒精性脂肪肝 二甲双胍 SGLT2抑制剂 

分 类 号：R587.1[医药卫生—内分泌] R575.5[医药卫生—内科学]